IL6 and neoplasm: In vitro experiments demonstrated that, compared to using PBMCs, NKT and γδT cells significantly enhanced the cytotoxicity of MSLN/CD3 bsAb against MSLN-positive tumor cells while releasing lower levels of pro-inflammatory cytokines IL-1β or IL-6, helping to reduce the risk of cytokine release syndrome.